{"id":"sodas-methylphenidate-hcl","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nervousness"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Elevated blood pressure"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylphenidate blocks the reuptake transporters for dopamine and norepinephrine, increasing their synaptic concentrations and enhancing neurotransmission in the brain. The SODAS (Spheroidal Oral Drug Absorption System) formulation provides extended-release delivery, allowing for once-daily dosing with a more gradual and sustained plasma concentration profile compared to immediate-release formulations.","oneSentence":"SODAS methylphenidate HCl is a sustained-release formulation of methylphenidate that inhibits the reuptake of dopamine and norepinephrine in the central nervous system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:08:16.868Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD)"},{"name":"Narcolepsy"}]},"trialDetails":[{"nctId":"NCT01673594","phase":"PHASE4","title":"Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2012-09","conditions":"ADHD, Stimulant-Induced Euphoria","enrollment":37},{"nctId":"NCT00302354","phase":"PHASE4","title":"A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2004-12","conditions":"Healthy Volunteers","enrollment":50},{"nctId":"NCT00536419","phase":"PHASE4","title":"Impact of Attention Deficit/Hyperactivity Disorder and Substance Use Disorder on Motorcycle Traffic Accidents","status":"UNKNOWN","sponsor":"Federal University of Rio Grande do Sul","startDate":"2007-09","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"SODAS methylphenidate HCl","genericName":"SODAS methylphenidate HCl","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SODAS methylphenidate HCl is a small molecule that inhibits the sodium-dependent dopamine transporter, a mechanism that is classified as a dopamine transporter inhibitor. It is used to treat conditions such as Attention Deficit Hyperactivity Disorder (ADHD) and Stimulant-Induced Euphoria, among others.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}